Objectives: The aim of this study was to compare 29 muscle-invasive bladder cancer patients who received neoadjuvant chemotherapy (NAC) followed by immediate robot-assisted radical cystectomy (RARC) with those who underwent minimum-incision endoscopic RC (MIE-RC). Methods: We retrospectively reviewed the charts of 430 consecutive patients who underwent RC and bilateral pelvic node dissection (PLND) between May 1994 and July 2016. Our study focused on patients with MIBC who had histologically confirmed stage T2-T4aN0M0 urothelial carcinoma of the bladder and received NAC prior to surgery. Accordingly, 225 patients were included in this analysis, of whom, 29 underwent RARC (RARC group) and 196 underwent MIE-RC (MIE-RC group). The primary endpoints in this study were the positive surgical margin (PSM) rate and lymph node (LN) count. Results: In the RARC group, 20 patients underwent RARC with intracorporeal urinary diversion and nine patients underwent RARC with extracorporeal urinary diversion. The median surgical duration for RC and bilateral PLND was 125 min in the RARC group and 98 min in the MIE-RC group (P < 0.001). The rate of PSM was 0% in the RARC group and 0.5% in the MIE-RC group. The median LN counts were 15 in the RARC group and 18 in the MIE-RC group. No intra-operative complication or mortality was associated with RARC or MIE-RP. All complications were grade 2 according to the Clavien-Dindo classification. Conclusions: Our initial experience with NAC followed by RARC appears to be favorable, with acceptable operative and perioperative clinical outcomes when compared with those of MIE-RC.
Introduction
Radical cystectomy (RC) remains the gold standard treatment for muscle-invasive bladder cancer (MIBC). Although the surgical technique of RC and perioperative care have improved in recent years, the 5-year survival rate of patients with MIBC is around 60% (1, 2) . Neoadjuvant chemotherapy (NAC) followed by RC is recommended for MIBC patients according to the guidelines of the European Association of Urology (EAU) and the National Comprehensive Cancer Network (NCCN) (3, 4) . There is also increasing evidence supporting the use of NAC in locally advanced bladder cancer (BC). A meta-analysis of randomized trials showed that cisplatin (CDDP)-based NAC, including methotrexate, vinblastine, doxorubicin and CDDP (MVAC) or CDDP, methotrexate and vinblastine (CMV), improved overall survival (OS) by 5% in T2-T4a BC patients (5, 6) .
Although open RC (ORC) remains the most commonly adopted surgical approach, it is associated with high morbidity and significant mortality (7) . Minimally invasive surgical approaches have been rapidly adopted for the treatment of MIBC, improving perioperative morbidity and ease of recovery (8) . Robot-assisted RC (RARC) has emerged as an alternative to ORC based on its possible reduction in estimated blood loss (EBL), blood transfusion rate, postoperative analgesia and quicker recovery of bowel function (9, 10) . The largest multi-institutional cohort study from the International Robotic Cystectomy Consortium (IRCC) reported that long-term oncological outcomes are similar to historical ORC data (1, 11) . On the other hand, measures of surgical quality for RARC include positive surgical margin (PSM) and lymph node (LN) yields, both of which have implications for oncological outcomes. In fact, a retrospective review of MIBC patients who underwent RARC at the Roswell Park Cancer Institute reported that long-term oncological outcomes were affected by the pathologic tumor and nodal status after RARC (12) . We previously reported the utility of NAC followed by immediate minimum incision endoscopic radical cystectomy (MIE-RC) in patients with MIBC (13) (14) (15) . The aim of this study was to evaluate our initial experience of 29 MIBC patients who received NAC followed by RARC compared with MIE-RC.
Methods

Patients
In this retrospective study, we reviewed the clinical and pathological records of 430 consecutive MIBC patients who underwent RC and bilateral pelvic lymphadenectomy (PLND) with or without NAC between May 1994 and July 2016 at Hirosaki University and Ibaraki prefectural Hospital. All patients underwent RC and bilateral PLND. Our study focused on patients with MIBC who had histologically confirmed stage T2-T4aN0M0 urothelial carcinoma of the bladder and received NAC prior to surgery.
The study protocol and informed consent documents were reviewed and approved by the Hirosaki University institutional review board.
Treatment schedule
All treatments were performed at our institution. All patients received two cycles of gemcitabine (GEM) and PLND at an interval of 1 month (13, 14) . A patient was identified as cisplatin-ineligible if they met at least one of the following criteria: European Cooperative Oncology Group (ECOG) performance status of 2, creatinine clearance <60 mL/min, hearing loss grade ≥2, neuropathy grade ≥2, and/or New York Heart Association (NYHA) Class III heart failure (17).
Surgical procedure
Our surgical technique with MIE-RC has been previously described in detail (15) . Briefly, a 7-cm midline incision is made suprapubically with the patient under general anesthesia. After creating a sufficient retropubic space, a self-retaining retractor is placed so as to retract the peritoneum cephalad, providing a small window for MIE-RC. A 30°laparoscope is usually positioned on the head side of the patients. The bladder wall is separated at the dome of the bladder from the peritoneum. The bladder is mobilized along the nonincised peritoneum. RARC was performed as follows. In all, seven trocars were used; the camera port (12 mm) was placed 2 cm above the umbilicus, two robotic trocars (8 mm) were placed 8 cm apart from the camera port at the umbilical level, and the trocar for the fourth arm (8 mm) was placed 3 cm vertically above the iliac crest on the right. Three assistant trocars were placed; a 15-mm trocar was placed vertically above the iliac crest on the left and two trocars (12 mm) were placed in the bilateral hypochondria. The patients were placed in the Trendelenburg position (25°). The whole procedure was carried out using a 0°scope. The peritoneum was incised in a circle at the dome of the bladder and the anterior cavity of the bladder was sufficiently exposed, until reaching the pubic bone and endopelvic fascia. The endopelvic fascia is incised and the dorsal vein complex was ligated using 2-0 V-Loc ® . The posterior layer of Denonvillier fascia was then incised in the midline between the rectum or vagina and the bladder [the uterus, fallopian tubes, ovaries and vagina were preserved in all female patients (18) ]. For the next step, the ureters were identified, mobilized, and divided close to the bladder. The distal segments of the ureters were sent to the pathology laboratory for immediate frozen-section analysis of the proximal margins. The lateral vascular bundles were incised close to the bladder to preserve the pelvic nerves located lateral to the seminal vesicles. The plane of urethral dissection was directed under the dorsal vein complex and through the anterior prostatic fibromuscular stroma. This plane is further carried through the prostatic urethra, transecting the most caudal aspect of the prostatic peripheral zone posteriorly, to create a long urethra.
PLND, including the hypogastric, external iliac and obturator nodes, was routinely performed in both procedures. The choice of urinary diversion was determined according to the surgeon's and/or patient's preference.
Patient evaluation
The following baseline information was obtained: complete history and physical examination, ECOG performance status, abdominal and pelvic computed tomography (CT) or magnetic resonance imaging (MRI) and chest radiography or CT.
Tumors were measured at baseline and before RC. The diagnosis of MIBC was confirmed by a single pathologist at Hirosaki University after reviewing the results of the transurethral resection (TUR) and MRI at baseline. We extensively examined the specimens obtained during cystoprostatectomy to identify the presence of MIBC. Pathological examination of complete transmural sections of the bladder wall was performed to accurately determine the pathological stage. In addition, histological examination of several sections from various sites within the bladder, including the dome, anterior wall, lateral walls, posterior wall, trigone and both ureters, was performed to identify superficial disease or a second primary tumor.
All tumors were staged according to the 2002 American Joint Committee on Cancer Staging Manual (19) . All LNs from each designated site were submitted for examination and representative sections of the surrounding fibroadipose tissue were also examined. Absence of cancer in the bladder and LN specimens was classified as pT0.
Follow-up
Each patient was evaluated every 3 months by ultrasonography to check for hydronephrosis and to monitor renal and liver function. CT was performed every 6 months for the early detection of recurrence.
Statistical analysis
The primary endpoint in this study was the rate of PSM and LN count. The secondary endpoints were the OS and surgical outcomes, including operative time, EBL, perioperative complications, pathological T stage, and LN involvement. Data were analyzed using IBM SPSS Statistics 20 (IBM Corp., Armonk, NY, USA). Differences between the RARC and MIE-RC cohorts were compared using the chi-square test for categorical variables and the Student's t-test or Wilcoxon rank-sum test for continuous variables. OS after RC was examined using the Kaplan-Meier method. All P values were 2-sided, and the significance level was set at P < 0.05.
Results
Patient characteristics
The pretreatment characteristics of the patients are listed in Table 1 . In this study, 29 patients underwent RARC (RARC group) and 196 underwent MIE-RC (MIE-RC group). All patients were diagnosed with muscle-invasive urothelial carcinoma on the basis of histological examination of the specimens obtained from TUR.
The median age of the enrolled patients was 69 years (interquartile rate [IQR], 62-74 years), and the median follow-up period was 53 months (IQR, 26.4-92 months). The median interval from the diagnosis of MIBC to RC was 64 days (IQR, 58-75 days). The number of the patients who were ineligible for cisplatin were 13 (44.8%) in the RARC group and 88 (44.9%) in the MIE-RC group. All MIBC patients at our institution received neoadjuvant GEM and CBDCA from 2005. On the other hand, the MIBC patients who were eligible for CDDP received neoadjuvant GEM and CDDP from June 2013.
Clinical response in both groups
Overall, 49 patients (21.8%), including 15 in the RARC cohort and 34 in the MIE-RC cohort, could not be evaluated for clinical response, because CT or MRI did not demonstrate any obvious, measurable tumors after diagnostic TUR. In the RARC cohort, four patients (13.8%) showed a complete response, four (13.8%) showed a partial response and two (6.9%) showed stable disease. In the MIE-RC cohort, 27 patients (13.8%) showed a complete response, and 80 (40.8%) showed a partial response. In addition, 54 patients (27.6%) showed stable disease, and 1 (0.5%) showed progressive disease.
Surgical outcomes
Surgical outcomes are shown in Table 2 . In the RARC group, nine patients underwent extracorporeal urinary diversion (ileal neobladder in five patients, ureterocutaneostomy in three and ileal conduit in one) and 20 patients underwent totally intracorporeal urinary diversion (ileal neobladder in 17 patients, and ileal conduit in three). RARC had a significantly longer operative time compared with that of MIE-RC. On the other hand, EBL in RARC was significantly lower compared with that in MIE-RC.
No intra-operative complications were associated with this procedure in both groups. Table 3 lists the perioperative complications in both groups. All complications were grade 2 according to the RARC, robot-assisted radial cystectomy; MIE-RC, minimum incision endoscopic radical cystectomy; IQR, interquartile range; NAC, neoadjuvant chemotherapy; Gem, gemcitabine; CDDP, cisplatin: CBDCA, carboplatin; MIBC, muscle-invasive bladder cancer; RC, radical cystectomy.
Clavien-Dindo classification (20) . No patients died within 90 days of surgery. There were no patients with any cystectomy-related late complications.
Pathological evaluation
All patients were evaluable for pathological outcomes. Table 4 lists the histopathological details. Overall, the surgical specimens of 52 (23.1%) patients showed stage pT0 disease. One patient had a PSM in the MIE-RC group. Twenty-one patients (9.3%) had LN involvement that was not evident on preoperative evaluation in both groups. Overall, 54 patients (23.1%) achieved pT0 in both groups. In the RARC cohort with pT0 disease, four patients were diagnosed as cT2 and six as cT3b. In the MIE-RC cohort with pT0 disease, 25 patients were diagnosed as cT2, 16 as cT3, and one as cT4.
Oncological outcomes
By the end of the follow-up period, three patients (10.3%) in the RARC group and 23 patients (11.7%) in the MIE-RC group had died of BC. Eleven patients (4.9%), including one patient in the RARC group and 10 in the MIE-RC group, developed clinical recurrence.
Discussion
RC remains one of the most effective oncological treatments for MIBC and for high grade, recurrent non-muscle-invasive tumors (1,2) . In recent years, several authors have described the feasibility of robotic approaches in patients undergoing RC for BC (8-10). Yuh et al. performed a systematic review and cumulative analysis of oncological and functional outcomes of RARC (21) . At 1, 3 and 5 years, OS was 82-90%, 61-80% and 39-66%, respectively. Disease-specific survival (DFS) was 79-96%, 67-76% and 53-74%, respectively (21) . However, only 6/18 series (33%) reported a mean follow-up >36 months (21) . On the other hand, Raza et al. reported the long-term oncological outcomes using the IRCC database (11) . At a median follow-up period of 67 months, OS and DFS rates were 50% and 67%, respectively (11). Gandaglia et al. reported the perioperative and oncological outcomes for MIBC patients who underwent ORC and RARC at two high-volume centers with a median follow-up period of 54 months (22) . When the patients were stratified according to the surgical approach, no differences were observed in 5-year OS and DFS rates between ORC and RARC (58.4% vs. 59.2% and 57.1% vs. 54.2%, respectively) (22) . A long-term analysis of survival in 1100 chemotherapy-naïve ORC patients demonstrated 10-year cancer-specific survival and OS rates of 67% and 44%, respectively (1). These reports concluded that RARC and ORC provide similar oncological outcomes, including OS and DFS (11, 12, 22) . Although the surgical technique with RC and perioperative care have improved in recent years, the oncological outcomes, especially OS, for MIBC patients who underwent RC alone was still low.
Several studies reported pathological tumor stage, LN involvement, and margin status as independent predictors of oncological outcomes after ORC (21, 23) . From the systematic review, the weighted average of PSM was 5.6% (21) . In RARC series, PSMs were reported in 1-1.5% of patients with pT2 disease and 0-25% of patients with pT3 and higher disease (24, 25) . On the other hand, PSM rates by stage were 2.3% for pT2, 7.6% for pT3, and 24% for pT4 disease in an analysis of 4400 ORC patients (23) . No significant difference was observed when comparing the surgical margin rate between RARC and ORC. However, higher LN yield is associated with improved DFS and OS (8). Bochner et al. reported that RARC plus extended PLND is feasible in most patients and has a similar LN yield to the open procedure (8) . However, with regard to RARC followed by PLND at the Roswell Park Cancer Institute, 9% had no PLND, 37% had node sampling, and 54% had a standard bilateral PLND (11) . Only 26% had >15 nodes removed (11) . In addition, the recurrence risks reported for patients with disease higher than pT3, with PSM, and with PLND were 32%, 68% and 29%, respectively (11) . MIBC is a systematic disease, and metastases or local recurrence in patients undergoing RC are often caused by micrometastases at the time of surgery. Therefore, it is important to apply systemic therapy early, in order to eradicate the risk of micrometastases outside the surgical field. The most commonly referenced NAC trial is the SWOG 8710 trial, in which neoadjuvant MVAC followed by RC was compared with RC alone (5) . Although the difference in 5-year OS was not statistically significant (P = 0.06), the results of this study have been used as evidence of the superiority of NAC over RC alone. A meta-analysis of randomized trials showed that cisplatin-based NAC improves OS by 5% in T2-T4a BC patients (26) . In our previous studies, the oncological outcomes, including OS and DFS, were significantly improved in MIBC patients who received NAC followed by immediate RC, when compared with patients who underwent RC alone (13, 14, 27) . In this study, pathological staging based on the surgical specimens was pT0 in 52 (23.1%) patients in the both groups. Overall, only one patient had a PSM on operative pathology in our study. NAC was performed for all patients with MIBC in the present series. The NAC may partly have had a crucial role in the decreased PSM rate in the present study. RARC with NAC for locally advanced tumors may have the advantage of achieving negative surgical margins more frequently than RC alone.
The current study has several limitations. First, it was a retrospective study, with an inherent potential for bias. Second, the use of clinical staging may be associated with understaging or overstaging. Third, a relatively small number of patients were enrolled in this study and the follow-up period was relatively short. Therefore, the present study has vital weaknesses in demonstrating the favorable oncological outcome of the present procedure. Our initial experience with NAC followed by RARC appears to be favorable, with acceptable operative and perioperative clinical outcomes compared with those of MIE-RC.
